194 related articles for article (PubMed ID: 3633952)
1. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
Loehrer PJ; Einhorn LH; Williams SD
J Clin Oncol; 1986 Apr; 4(4):528-36. PubMed ID: 3633952
[TBL] [Abstract][Full Text] [Related]
2. VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
Einhorn LH
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S45-50. PubMed ID: 3815718
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Ghosn M; Droz JP; Theodore C; Pico JL; Baume D; Spielmann M; Ostronoff M; Moran A; Salloum E; Kramar A
Cancer; 1988 Jul; 62(1):24-7. PubMed ID: 3133101
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma.
Harstrick A; Schmoll HJ; Wilke H; Köhne-Wömpner CH; Stahl M; Schöber C; Casper J; Bruderek L; Schmoll E; Bokemeyer C
J Clin Oncol; 1991 Sep; 9(9):1549-55. PubMed ID: 1651992
[TBL] [Abstract][Full Text] [Related]
5. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results.
Pizzocaro G; Salvioni R; Piva L; Faustini M; Nicolai N; Gianni L
Ann Oncol; 1992 Mar; 3(3):211-6. PubMed ID: 1316779
[TBL] [Abstract][Full Text] [Related]
6. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
7. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
8. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
9. [Salvage chemotherapy of non-seminomatous germ cell tumors. Phase II trial of a combination of etoposide, ifosfamide and high-dose cisplatin].
Ribrag V; Droz JP; Bouleuc C; Theodore C; Ghosn M; Pico JL; Azab M; Ostronoff M; Hayat M
Presse Med; 1990 Jul 7-14; 19(27):1263-6. PubMed ID: 2143824
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.
McCaffrey JA; Mazumdar M; Bajorin DF; Bosl GJ; Vlamis V; Motzer RJ
J Clin Oncol; 1997 Jul; 15(7):2559-63. PubMed ID: 9215825
[TBL] [Abstract][Full Text] [Related]
11. Treatment of testicular cancer: a new and improved model.
Einhorn LH
J Clin Oncol; 1990 Nov; 8(11):1777-81. PubMed ID: 1700077
[TBL] [Abstract][Full Text] [Related]
12. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
[TBL] [Abstract][Full Text] [Related]
13. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.
Motzer RJ; Cooper K; Geller NL; Bajorin DF; Dmitrovsky E; Herr H; Morse M; Fair W; Sogani P; Russo P
Cancer; 1990 Dec; 66(12):2476-81. PubMed ID: 2174300
[TBL] [Abstract][Full Text] [Related]
14. Lowered Cisplatin Dose and No Bleomycin in the Treatment of Pediatric Germ Cell Tumors: Results of the GCT-99 Protocol From the Brazilian Germ Cell Pediatric Oncology Cooperative Group.
Lopes LF; Macedo CR; Aguiar Sdos S; Barreto JH; Martins GE; Sonaglio V; Milone M; Lima ER; Almeida MT; Lopes PM; Watanabe FM; D'Andrea ML; Pianovski MA; Melaragno R; Vianna SM; Moreira ME; Bruniera P; de Oliveira CZ
J Clin Oncol; 2016 Feb; 34(6):603-10. PubMed ID: 26729441
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
16. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
Loehrer PJ; Lauer R; Roth BJ; Williams SD; Kalasinski LA; Einhorn LH
Ann Intern Med; 1988 Oct; 109(7):540-6. PubMed ID: 2844110
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Hlavatá Z; Mego M; Recková M; Koza I
Neoplasma; 2005; 52(6):497-501. PubMed ID: 16284696
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
19. Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy.
Al-Hader AA; Jain A; Al-Nasrallah N; Einhorn LH
Am J Clin Oncol; 2015 Aug; 38(4):364-6. PubMed ID: 23799289
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
